Patents by Inventor Ijeoma Uchegbu
Ijeoma Uchegbu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230330132Abstract: The present invention relates to a derivatised amphiphilic carbohydrate compound with molecular weight less than 50 kDa which is based on a glycol chitosan for use in the prevention or treatment of a viral infection. The invention further relates to the use of the compound when formulated with other components in pharmaceutical compositions for the prevention or treatment of viral infections, and further to a method of reducing viral replication in human tissues.Type: ApplicationFiled: August 24, 2021Publication date: October 19, 2023Inventors: Ijeoma UCHEGBU, Andreas SCHATZLEIN, Krzysztof PYRC, Aleksandra MILEWSKA, Emilia BARRETO DURAN
-
Publication number: 20210212938Abstract: The present invention relates to an aqueous composition comprising a macrolide immunosuppressant drug at a concentration of less than 2% w/v and an amphiphilic carbohydrate compound having a molecular weight in the range 1-50 kDa, for use in treatment of an eye disorder by topical application to the eye, wherein the amphiphilic carbohydrate compound is present at a concentration below 10% w/v of the composition. A preferred carbohydrate compound is quaternary ammonium palmitoyl glycol chitosan (GCPQ). Pharmaceutical compositions and methods of treatment are also provided. The treatment may be for instance dry eye syndromes (DES), vernal keratoconjunctivitis (VKC), eczema, atopic keratoconjunctivitis (AKC), Sjögren syndrome, post-operative refractive surgery, corneal transplant or contact lens intolerance.Type: ApplicationFiled: March 26, 2021Publication date: July 15, 2021Inventors: Ijeoma Uchegbu, Andreas Schatzlein, Lorenzo Capretto
-
Patent number: 10987304Abstract: The present invention relates to an aqueous composition comprising a macrolide immunosuppressant drug at a concentration of less than 2% w/v and an amphiphilic carbohydrate compound having a molecular weight in the range 1-50 kDa, for use in treatment of an eye disorder by topical application to the eye, wherein the amphiphilic carbohydrate compound is present at a concentration below 10% w/v of the composition. A preferred carbohydrate compound is quaternary ammonium palmitoyl glycol chitosan (GCPQ). Pharmaceutical compositions and methods of treatment are also provided. The treatment may be for instance dry eye syndromes (DES), vernal keratoconjunctivitis (VKC), eczema, atopic keratoconjunctivitis (AKC), Sjögren syndrome, post-operative refractive surgery, corneal transplant or contact lens intolerance.Type: GrantFiled: November 2, 2015Date of Patent: April 27, 2021Assignee: Nanomerics Ltd.Inventors: Ijeoma Uchegbu, Andreas Schatzlein, Lorenzo Capretto
-
Patent number: 10213474Abstract: The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body. The composition can be used to treat a variety of disorders, including schizophrenia, obesity, pain and sleep disorders, psychiatric diseases, neurodegenerative conditions, brain cancers and infective diseases.Type: GrantFiled: November 3, 2014Date of Patent: February 26, 2019Assignee: Nanomerics LTDInventors: Ijeoma Uchegbu, Andreas Schatzlein, Lisa Godfrey, Katerina Lalatsa, Antonio Iannitelli
-
Publication number: 20160279189Abstract: The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body.Type: ApplicationFiled: November 3, 2014Publication date: September 29, 2016Inventors: Ijeoma UCHEGBU, Andreas SCHATZLEIN, Lisa GODFREY, Katerina LALATSA, Antonio IANNITELLI
-
Patent number: 8920819Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.Type: GrantFiled: August 31, 2012Date of Patent: December 30, 2014Assignee: University College LondonInventors: Ijeoma Uchegbu, Aikaterini Lalatsa, Andreas Schatzlein
-
Publication number: 20130203647Abstract: A composition comprises nanofibres for the delivery of a peptide across the blood brain barrier in a method of therapy of the human or animal body, wherein the nanofibres comprise a peptide conjugated to a lipophilic group. Further, a compound comprises a Dalargin or a derivative having one or more substituted, deleted or inserted aminoacyl units, and, conjugated to an aminoacyl group preferably via a side chain, a lipophilic group, optionally via a linker.Type: ApplicationFiled: July 11, 2011Publication date: August 8, 2013Applicant: UNIVERSITY COLLEGE LONDONInventors: Ijeoma Uchegbu, Andreas Schatzlein, Mariarosa Mazza
-
Publication number: 20130034590Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.Type: ApplicationFiled: August 31, 2012Publication date: February 7, 2013Inventors: Ijeoma Uchegbu, Aikaterini Lalatsa, Andreas Schatzlein
-
Patent number: 8278277Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.Type: GrantFiled: April 9, 2009Date of Patent: October 2, 2012Assignee: University College LondonInventors: Ijeoma Uchegbu, Aikaterini Lalatsa, Andreas Schatzlein
-
Publication number: 20100222281Abstract: Compositions comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy of the human or animal body are provided. Methods of medical treatment, wherein a composition according to the invention is administered to a human or animal body also form part of the invention. It is preferred that the drug is delivered to the brain.Type: ApplicationFiled: April 9, 2009Publication date: September 2, 2010Applicant: SCHOOL OF PHARMACY, UNIVERSITY OF LONDONInventors: Ijeoma Uchegbu, Aikaterini Lalatsa, Andreas Schatzlein
-
Patent number: 7741474Abstract: This invention relates to novel carbohydrate polymers with hydrophobic and hydrophilic side-groups suitable for solubilising, for example, hydrophobic drugs. The chain length of the carbohydrate polymeric backbone, and the type and number of the hydrophobic and hydrophilic side-groups are specifically chosen to improve the solubility properties of the carbohydrate polymers.Type: GrantFiled: September 22, 2003Date of Patent: June 22, 2010Assignee: The School of Pharmacy, University of LondonInventors: Ijeoma Uchegbu, Andreas Schatzlein, Ailsa Stewart, Clive Wilson
-
Publication number: 20080267903Abstract: Various polymers, including cationic polyamine polymers and dendrimeric polymers, are shown to possess anti-proliferative activity, and may therefore be useful for treatment of disorders characterised by undesirable cellular proliferation such as neoplasms and tumours, inflammatory disorders (including autoimmune disorders), psoriasis and atherosclerosis. The polymers may be used alone as active agents, or as delivery vehicles for other therapeutic agents, such as drug molecules or nucleic acids for gene therapy. In such cases, the polymers' own intrinsic anti-tumour activity may complement the activity of the agent to be delivered.Type: ApplicationFiled: October 14, 2005Publication date: October 30, 2008Inventors: Ijeoma Uchegbu, Andreas G. Schatzlein, Christine Dufes
-
Publication number: 20060167116Abstract: This invention relates to novel carbohydrate polymers with hydrophobic and hydrophilic side-groups suitable for solubilising, for example, hydrophobic drugs. The chain length of the carbohydrate polymeric backbone, and the type and number of the hydrophobic and hydrophilic side-groups are specifically chosen to improve the solubility properties of the carbohydrate polymers.Type: ApplicationFiled: September 22, 2003Publication date: July 27, 2006Inventors: Ijeoma Uchegbu, Andreas Schatzlein, Alisa Stewart, Clive Wilson
-
Publication number: 20060148982Abstract: This invention relates to the delivery of drugs. In particular, this invention relates to the oral delivery of poorly soluble drugs using novel amphiphilic polymers with both solubilising and absorption enhancing properties.Type: ApplicationFiled: September 22, 2003Publication date: July 6, 2006Inventors: Ijeoma Uchegbu, Andreas Schatzlein, Woei Cheng
-
Publication number: 20050019923Abstract: The present invention provides cationic dendrimers for delivering bioactive molecules, such as polynucleotide molecules, peptides and polypeptides and/or pharmaceutical agents, to a mammalian body. The dendrimers disclosed herein are suitable for targeting the delivery of the bioactive molecules to, for example, the liver, spleen, lung, kidney or heart.Type: ApplicationFiled: October 17, 2002Publication date: January 27, 2005Inventors: Ijeoma Uchegbu, Avril Munro, Andreas Schatzlein, Alexander Gray, Bernd Zinselmeyer